Preparation and Characterization of Rice Bran Protein Hydrolysates Enhanced via Alcalase and Lactiplantibacillus plantarum 13110 Co-Treatment: Antioxidant Properties and Ameliorative Effects on Ulcerative Colitis in Mice
Nutrients · 2026
DOI: 10.3390/nu18081278 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2026. Verfasst von Guanlong Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Heilongjiang Provincial Key Laboratory of Corn Deep Processing Theory and Technology, College of Food and Bioengineering, Qiqihar University, Qiqihar…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Protein Hydrolysates, Oryza, Antioxidants. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of the People's Republic of China.
Abstract (Originalsprache)
Background
Ulcerative colitis, a chronic inflammatory disorder of the intestine, represents a major health concern worldwide. This study aimed to explore the in vivo efficacy of rice bran protein hydrolysates in mitigating UC.
Methods
Rice bran protein hydrolysates with enhanced antioxidant activity were prepared via co-treatment with Alcalase and Lactiplantibacillus plantarum 13110.
Results
Compared with hydrolysates obtained using Alcalase in isolation (RHP), the co-treated rice bran (CRB) protein hydrolysates exhibited significantly higher antioxidant capacity. Structural characterization revealed marked alterations in molecular weight distribution, amino acid composition, and RHP spectral features, based on Fourier transform infrared spectroscopy, during fermentation with L. plantarum 13110. The 500 mg/kg·bw CRB intervention effectively attenuated oxidative stress and inflammatory responses in dextran sulfate sodium (DSS)-induced colitic mice, as evidenced by significantly reduced colonic levels (p < 0.05) of pro-inflammatory mediators (TNF-α, IL-1β, IL-6, and LPS), decreased serum concentrations of fatty acid-binding protein 2 (FABP2), diamine oxidase (DAO), and D-lactic acid (D-LA), and increased colonic IL-10 content (p < 0.05). These changes were associated with ulcerative colitis amelioration and improved intestinal barrier function.
Conclusions
Thus, CRB exhibits promising prophylactic effects against ulcerative colitis, suggesting its potential for therapeutic application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Heilongjiang Provincial Key Laboratory of Corn Deep Processing Theory and Technology, College of Food and Bioengineering, Qiqihar University, Qiqihar 161006, China.
- Engineering Research Center of Plant Food Processing Technology, Ministry of Education, Qiqihar University, Qiqihar 161006, China.
- College of Food Science, Heilongjiang Bayi Agricultural University, Daqing 163319, China.
ORCID-Profile: Guanlong Li
Förderung
- Ministry of Science and Technology of the People's Republic of China
Zitieren
APA
Li, G., Liu, X., Li, P., Wang, Q., Wang, C., & Zheng, X. (2026). Preparation and Characterization of Rice Bran Protein Hydrolysates Enhanced via Alcalase and Lactiplantibacillus plantarum 13110 Co-Treatment: Antioxidant Properties and Ameliorative Effects on Ulcerative Colitis in Mice. Nutrients. https://doi.org/10.3390/nu18081278
Vancouver
Li G, Liu X, Li P, Wang Q, Wang C, Zheng X. Preparation and Characterization of Rice Bran Protein Hydrolysates Enhanced via Alcalase and Lactiplantibacillus plantarum 13110 Co-Treatment: Antioxidant Properties and Ameliorative Effects on Ulcerative Colitis in Mice. Nutrients. 2026. doi:10.3390/nu18081278
BibTeX
@article{Li2026,
author = {Li, Guanlong and Liu, Xiaolan and Li, Peng and Wang, Quanxin and Wang, Changyuan and Zheng, Xiqun},
title = {Preparation and Characterization of Rice Bran Protein Hydrolysates Enhanced via Alcalase and Lactiplantibacillus plantarum 13110 Co-Treatment: Antioxidant Properties and Ameliorative Effects on Ulcerative Colitis in Mice},
journal = {Nutrients},
year = {2026},
doi = {10.3390/nu18081278}
}
EUVIMED